Carregant...
Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
BACKGROUND: Pancreatic cancer (PDAC) is the most lethal malignancy. New treatment options for it are urgently required. The aim was to develop an antibody–drug conjugate (ADC) targeting glypican-1 (GPC-1) as a new therapy for PDAC. METHODS: We evaluated GPC-1 expression in resected PDAC specimens an...
Guardat en:
| Publicat a: | Br J Cancer |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7189381/ https://ncbi.nlm.nih.gov/pubmed/32152502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0781-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|